Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
An Open-Label, Extension Study of the Effects of LMTM in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
Sponsor: TauRx Therapeutics Ltd
Terminated
This study has been terminated for administrative reasons only.
Listed as NCT02245568, this PHASE3 trial focuses on Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia and remains terminated or withdrawn. Sponsored by TauRx Therapeutics Ltd, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2023 [monthly]
Terminated PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Jul 2020 [monthly]
Terminated PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE3
Status: Enrolling By Invitation → Terminated
-
Feb 2017 — Mar 2018 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TauRx Therapeutics Ltd
For direct contact, visit the study record on ClinicalTrials.gov .